Astrazeneca Ab

Astrazeneca Aktiebolag

Dainippon Sumitomo Pharma Co., Ltd.

Sumitomo Dainippon Pharma Co., Ltd.

Stephen Brough

Thomas McInally

Roger Victor Bonnert

Timothy Jon Luker

Andrew Baxter

Stephen Thom

Yoshiaki Isobe

Ayumu Kurimoto

Piotr Antoni Raubo

Bryan Glyn Roberts

Richard Evans

Hiroki Wada

Ian Millichip

Kazuki Hashimoto

Nicholas David Kindon

Rukhsana Rasul

Thomas Mcinally

Michael P Mortimore

Alan Wellington Faull

Brian Springthorpe

Craig Johnstone

Matthew Wd Perry

Hitesh Jayantilal Sanganee

Garry Pairaudeau

Anil Patel

Mark Dickinson

Simon Teague

Tony Cook

Stephen Anthony St-Gallay

Andrew Davies

Andrew Davis

The present invention provides an 8-oxoadenine compound having immunomodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Zrepresents alkylene, Xrepresents oxygen atom, sulfur atom, SO, NR, CO, CONR, NRCO and the like, Y, Yand Yrepresent independently a single bond or an alkylene group, Xrepresents oxygen atom, sulfur atom, NR(Ris hydrogen atom or an alkyl group) or a single bond, Rrepresents a substituted or unsubstituted alkyl group, Rrepresents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group]or its pharmaceutically acceptable salt.

9-substituted 8-oxoadenine compound

The present invention relates to pyrazinone derivatives of formula (I): wherein R, R, R, R, R, Rand Rare as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Pyrazinone derivatives, pharmaceutically acceptance salts thereof and their uses

The present invention provides an 8-oxoadenine compound having immunemodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Zrepresents alkylene, Xrepresents oxygen atom, sulfur atom, SO, NR, CO, CONR, NRCO and the like, Y, Yand Yrepresent independently a single bond or an alkylene group, Xrepresents oxygen atom, sulfur atom, NR(Ris hydrogen atom or an alkyl group) or a single bond, Rrepresents a substituted or unsubstituted alkyl group, Rrepresents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group]or its pharmaceutically acceptable salt.

N-cyclopropyl-3-fluoro-5-[3-[[1-[2-[2- [(2-hydroxethyl)amino] ethoxy]phenyl] cyclopropyl] amino]-2-oxo-1 (2H)-pyrazinyl]-4-methyl-benzamide, or pharmaceutically acceptable salts thereof and their uses

Compounds and their uses 708

The invention relates to substituted phenoxyacetic acids (I) as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation. 

Compounds

The present invention relates to isoquinolinone derivatives of formula (I): wherein are as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Isoquinolinone derivatives

The invention relates to heteroaromatic carboxamides of formula (I), wherein A, R, Rand X are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

Substituted Thiophene compounds

The present invention relates to substituted indoles of formula (I) useful as pharmaceutical compounds for treating respiratory disorders 

Substituted indoles

The invention provides a compound of formula (I): wherein R, R, R, R, R, N, X and Y are as defined in the specification, processes, for their preparation, pharmaceutical compositions containing them, and their use in therapy, especially for the treatment of chemokine receptor related diseases and conditions.

Chemical compounds

The invention provides compounds of general formulawherein R, m, Q, T, n, R, R, V, W, X and Rare as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

The invention provides compounds of general formula (I) wherein: R represents optionally substituted, C -C alkyl or optionally substituted 3- to 10-membered saturated or unsaturated ring system comprising up to two ring carbon atoms that form carbonyl groups and comprising up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulfur; m is 0-1; Q represents OCH , C -C alkylene or C -C alkenylene; T represents C(O)NH, or when m is 0, T may additionally represent a bond or NH, or when m is 1 and Q represents C -C alkylene, T may additionally represent NH; n is 1-4; each R and R independently represents H or C -C alkyl; V represents N, and W represents N or CH; X represents O, C(O), CH(OH), SO , NH or N(C -C alkyl), provided that when W represents N, then X represents either C(O) or SO and when W represents CH, then X is other than SO ; R represents optionally substituted phenyl; R and R each independently represent H, C -C alkyl or hydroxyC -C alkyl, or R and R together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring; R and R each independently represent H or C -C alkyl; and R represents OH or &mdash;NR R ; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

The invention provides adamantane derivatives, a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy.

Adamantane derivatives

Growing community of inventors

Leicestershire, United Kingdom

Stephen Brough